CA Patent

CA3301698A1 — TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES

Assigned to Alnylam Pharmaceuticals Inc · Expires 2026-03-02 · 0y expired

What this patent protects

Patent listed against vutrisiran-sodium.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: CA3301698A1
Jurisdiction: CA
Classification: —
Expires: 2026-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.